Royalty Pharma plc (RPRX)$54.50
Market Cap: 18.95 BCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Royalty Pharma plc (RPRX).
HEALTHCARE
BIOTECHNOLOGY
DCF ready
Valuation
11.0x
EV/FCF, 9.1% FCF yield
Quality
4.1%
ROIC, 104.7% FCF margin
Growth
2.3%
5Y sales (revenue) CAGR
Balance sheet
0.9x
Debt/equity, 2.4x current ratio
Superinvestors
3
Top: Pat Dorsey (8.7%)
Strengths to research
- Free cash flow margin is healthy at 104.7%.
- Debt/equity looks manageable at 0.9x.
- 3 tracked superinvestors report a position.
- 8 annual periods are available for trend analysis.
Watchouts
No major valuation, balance sheet, or growth watchouts were detected by the static screen.
Annual data: 8 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for RPRX.
Grade D
40
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| RPRX Target | Royalty Pharma plc | $19.0B | 30.6x | 11.0x | 4.1% | 2.3% | 104.7% | N/A | 5.3x | N/A |
| BNTX | Biontech Se ADR | $24.3B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| INCY | Incyte Corp. | $12.0B | 15.2x | 6.3x | 24.9% | 14.0% | 27.5% | N/A | -1.9x | N/A |
| BMRN | BioMarin Pharmaceutical Inc. | $11.9B | 30.1x | 14.6x | 5.7% | 11.6% | 22.5% | N/A | -2.7x | N/A |
| MRNA | Moderna, Inc. | $10.8B | -6.5x | -4.0x | -32.6% | 19.3% | -106.2% | N/A | N/A | N/A |
| ALNY | Alnylam Pharmaceuticals | $35.4B | 127.7x | 72.5x | 39.8% | 49.8% | 12.5% | N/A | -3.0x | N/A |
| ROIV | Roivant Sciences Ltd | $8.3B | -55.5x | -9.0x | -6.6% | -19.1% | -9183.5% | N/A | N/A | N/A |
| TECH | Bio-Techne Corp. | $7.9B | 104.8x | 30.1x | 3.8% | 10.5% | 21.0% | 64.8% | -0.8x | N/A |
| HALO | Halozyme Therapeutics | $7.5B | 26.7x | 14.7x | 14.5% | 39.2% | 46.2% | N/A | 4.2x | N/A |
Financial Charts
No financial data available for RPRX (annual).
3 superinvestors own RPRX
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Samantha McLemore Patient Capital Management | 3,643,716 | $175M | 6.52% | 0.0% |
| Pat Dorsey Dorsey Asset Management | 2,276,570 | $109M | 8.70% | 0.0% |
| Torray Funds Torray Funds | 645,425 | $31M | 4.85% | 0.0% |